Symbols

VNDA

Vanda Pharmaceuticals·NASDAQ

--(--)

VNDA fundamentals

VNDA Q4 2025 Earnings

Vanda Pharmaceuticals (VNDA) released its earnings on Feb 11, 2026: revenue was 57.22M (YoY +7.59%), missed estimates; EPS was -2.39 (YoY -2887.50%), missed estimates.

Revenue / YoY

57.22M

+7.59%

EPS / YoY

-2.39

-2887.50%

Report date

Feb 11, 2026

VNDA Earnings Call Summary for Q4,2025

Fanapt Dominance: 24% revenue growth (2025) and 36% Q4 TRx growth, driven by new patient starts and direct-to-consumer campaigns.
Nereus Breakthrough: FDA-approved for motion sickness, with Phase III GLP-1 trial set to begin H1 2026. 2026 launch expected late Q2/Q3.
Pipeline Momentum: Vasanti NDA under review, Imsidolimab BLA filed, and Visante Phase III for MDD ongoing.
Financial Outlook: 2026 revenue guidance $230-$260 million (+13% YoY), with Fanapt sales targeting $150-$170 million (+36%-40% YoY).
Risks: HETLIOZ generic erosion (2025 sales -7%), PONVORY growth constrained by market access challenges.

Earnings

EPS

Revenue

Revenue & Expenses

VNDA has released its 2025 Q4 earnings report, with revenue of 57.22M, reflecting a YoY change of 7.58%, and net profit of -141.19M, showing a YoY change of -2774.33%. The Sankey diagram below clearly presents VNDA's revenue sources and cost distribution.

Key Indicators

Vanda Pharmaceuticals (VNDA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Vanda Pharmaceuticals (VNDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Vanda Pharmaceuticals (VNDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Vanda Pharmaceuticals (VNDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown